CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced results from its single-dose, dose-escalation Phase 1 clinical trial evaluating the safety and mechanism ...
We have seen 139 institutional investors add shares of $IMO stock to their portfolio, and 151 decrease their positions in their most recent quarter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback